ストックスクリーナーアプリを入手
39.84
3.89%
1.49
アフターアワーズ：
40.34
0.50
+1.26%
前日終値:
$38.35
開ける：
$36.78
24時間の取引高:
466.59K
Relative Volume:
1.33
時価総額：
$142.94M
収益：
$7.97M
当期純損益:
$-75.74M
株価収益率:
-20.86
EPS:
-1.91
ネットキャッシュフロー:
$-85.33M
1週間 パフォーマンス:
+16.94%
1か月 パフォーマンス:
+118.90%
6か月 パフォーマンス:
+282.98%
1年 パフォーマンス:
+161.25%
1日の値動き範囲:
$36.35
$41.64
1週間の範囲:
$28.00
$41.64
52週間の値動き範囲:
$6.76
$41.64
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
39.84 | 142.94M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week - Yahoo Finance
Charles Schwab Investment Management Inc. Lowers Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World
Aligos Therapeutics stock soars to 52-week high of $35.47 - Investing.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) - Seeking Alpha
How To Trade (ALGS) - Stock Traders Daily
Aligos stock hits 52-week high at $30.01 amid robust gains - Investing.com India
Baker BROS. Advisors LP Decreases Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - MarketBeat
Aligos Therapeutics Inc (ALGS) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 140.3% in November - MarketBeat
Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth? - Simply Wall St
Aligos Therapeutics to Present at Investor Conferences in December - The Manila Times
Aligos Therapeutics to Present at Two Major Healthcare Investor Conferences in December | ALGS Stock News - StockTitan
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Aligos Therapeutics files $400M mixed securities shelf - MSN
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - The Manila Times
Aligos Reports 100% HBV Suppression Success, Strong MASH Treatment Results in Clinical Trials | ALGS Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com
ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com
Compass Therapeutics Inc (CMPX) Quarterly 10-Q Report - Quartzy
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Aligos Therapeutics Inc (ALGS) Quarterly 10-Q Report - Quartzy
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright - Defense World
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Yahoo Canada Finance
(ALGS) Technical Pivots with Risk Controls - Stock Traders Daily
Aligos Therapeutics Reports Q3 2024 Progress - TipRanks
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - The Manila Times
Aligos Reports 46% Liver Fat Reduction in MASH Trial; Q3 Loss Widens to $19.3M | ALGS Stock News - StockTitan
Aligos planning for Phase 2 trial of treatment for hepatitis B - Liver Disease News
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal
(ALGS) On The My Stocks Page - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):